Search

Hemothorax (HT) and pulmonary hematoma represent rare complications of anticoagulant therapy. We present a rare case of a 53-year-old man with COVID-19 pneumonia who showed, in a follow-up computed tomography (CT) scan 13 days after hospitalization, a left HT and a small hyperdense area in a subpleural location and compatible with a small subpleural hematoma. This patient was being treated with a subcutaneous administration of low-molecular-weight heparin (100UI/kg/BID). No vascular malformations were visualized on the CT pulmonary angiography. Herein, we report the first case of both a spontaneous HT and a lung subpleural hematoma in a COVID-19 patient, probably caused by anticoagulant therapy. [ABSTRACT FROM AUTHOR]

Compounds of general formula FeX2(L) {L=2,6-bis(3,5-dimethyl-N-pyrazolyl)pyridine, C15H17N5; bis[3,5-dimethyl-N-pyrazolyl)methyl]-isopropylamine, C15H25N5; bis(benzimidazol-2-yl-methyl)amine, C16H15N5, 1,3-bis(benzimidazolyl)propane, C17H16N4; bis(benzimidazolyl-2-methyl)ether, C16H14N4O; bis(benzimidazolyl-2-methyl)thioether, C16H14N4S} have been synthesized by reacting the amine with Fe4Cl8(THF)6 or FeI2(CO)4 in toluene. The complexes FeCl2(C15H17N5)·MeCN and FeCl2(C16H15N5)(MeOH) have been characterized by single crystal X-ray diffraction together with the parent triamines, C15H17N5 and C16H15N5, for comparison. The reaction of FeI2(CO)4 with bis(benzimidazolyl-2-methyl)thioether, C16H14N4S, led to the product of partial carbonyl substitution FeI2(CO)2(C16H14N4S). [Copyright &y& Elsevier]